To evaluate whether phased withdrawal of pharmacological heart failure therapy in patients with non-high cardiovascular risk breast cancer and ‘recovered’ HER2-targeted therapy-related cardiac dysfunction, after completion of cancer therapy, is non-inferior to continuation with regard to risk of recurrence in cardiac dysfunction. The gene discussed is ERBB2; the disease is cancer.